Register-based observational study of associations between inflammatory remission, formal treatment targets and the use of disease-modifying antirheumatic drugs among patients with early rheumatoid arthritis
Authors' conclusion
Failing to reach formal treatment targets, despite being in inflammatory remission, is common among patients with early RA, and is associated with an increased likelihood of starting a new DMARD-treatment.
Study context
- Population
- Patients newly diagnosed with rheumatoid arthritis (RA), Swedish Rheumatology Quality Register
- Participants
- 11,784 patients
- Exposure
- Inflammatory remission without DAS28 remission vs inflammatory remission with DAS28 remission
- Outcome
- Likelihood of starting a new disease-modifying antirheumatic drug (DMARD)
Methodological detailsSwedish Rheumatology Quality Register, modified Poisson regression
- Swedish Rheumatology Quality Register
- Modified Poisson regression
Main finding
As reported in the abstract
Starting a new DMARD · 6, 12 and 24 months
Failed DAS28 remission vs Reached DAS28 remissionRelative risk (95% CI)
6 months
1.59(1.29–1.96)
12 months
1.52(1.23–1.87)
24 months
1.47(1.20–1.80)
Observational data: associations, not effects.
Further findings
Proportion in inflammatory remission (all patients) · 3, 6, 12 and 24 months
- 3 months
- 34%
- 6 months
- 39%
- 12 months
- 44%
- 24 months
- 47%
Proportion in inflammatory remission failing to reach DAS28 remission · 3, 6, 12 and 24 months
- 3 months
- 20%
- 6 months
- 22%
- 12 months
- 20%
- 24 months
- 19%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Register-based observational study of associations between inflammatory remission, formal treatment targets and the use of disease-modifying antirheumatic drugs among patients with early rheumatoid arthritis. RMD Open. Published 16 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →